The main objective of the study is to determine if a diuretic adaptation protocol in the decompensation of chronic heart failure is more effective but also safer than the current non-protocolized practice.
Diuretics are the main treatment for congestive decompensation of chronic heart failure. For symptomatic purposes, the goal is to decrease the volume overload. In these patients, loop diuretics are used in high doses, sometimes in combination with other classes of diuretics such as thiazides to achieve synergistic, faster and more effective action, and to combat diuretic's resistance. This use, well known to cardiologists and based on a rich pharmacology, more than 40 years old, lacks robust scientific data in real life. Current studies are mainly based on patients with renal insufficiency or limited to cardio-renal syndrome. The CARRESS-H study in 2012 is one of them. The protocol for the use of diuretics from this study was included in 2017 as a benchmark in a publication of the NEJM. It therefore seems necessary to consider the exercise of this protocol in the management of the decompensation of chronic cardiac heart failure. There is, to the investigator's knowledge, no similar study to test this protocol as a "real life" exercise.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
299
Protocol for the use of diuretics
Protocol for the use of diuretics
Ch Annecy
Annecy, France
Chu Clermont-Ferrand
Clermont-Ferrand, France
CHU de GRENOBLE
Grenoble, France
Ch Issoire
Issoire, France
Change in the serum creatinine level
serum creatinine
Time frame: at 96 hours of admission
change in weight
The weight will be measured in kilograms
Time frame: at 96 hours of admission
Time of intravenous administration of diuretics
Length of time of intravenous administration of diuretics in days
Time frame: at 1 month
severity of acute kidney injury during hospitalisation
Acute kidney injury requiring interruption of treatment
Time frame: at 1 month
Severe Hypokaliemia
Severe hypokalaemia means hypokalaemia that requiring interruption of treatment, dialysis or transfer in intensive care.
Time frame: at month
Number of rehospitalization for heart failure or kidney failure
Number of rehospitalization for heart failure or kidney failure
Time frame: At 30 days after the date of randomisation
Mortality (all cause and heart failure)
Number of death of participants
Time frame: At 30 days after the date of randomisation
Dose of diuretics
Comparison of diuretics dose of Furosemide and/or Thiazid diuretic. The dose will be measured on milligrams per day.
Time frame: At 30 days after the date of randomisation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
CH PUY
Le Puy-en-Velay, France
Infirmerie Protestante de Lyon
Lyon, France
Ch Lyon Sud
Lyon, France
Ch Moulins
Moulins, France
CH RIOM
Riom, France
Description and comparison of global cost between the two groups
Description and comparison of global cost between the two groups
Time frame: At 30 days after the date of randomisation
Estimated plasma volume change
Estimated plasma volume change captured via hemoglobin-to-hematocrit ratio (Hb/Ht) using the Strauss formula
Time frame: At 30 days after the date of randomisation
change in bodyweight
The weight will be measured in kilograms
Time frame: at 96 hours after admission of patient
Blood chemistry (serum creatinine)
serum creatinine
Time frame: month 1
Blood chemistry (glomerular filtration rate)
glomerular filtration rate (GFR) estimated using the CKD-EPI equation
Time frame: month 1
Blood chemistry
NT-proBNP or BNP (as available)
Time frame: month 1
Blood chemistry (plasma volume estimated)
plasma volume estimated via hemoglobin-to-hematocrit ratio (Hb/Ht)
Time frame: month 1